Review
Endocrinology & Metabolism
Ruolin Lv, Lili Xu, Lin Che, Song Liu, Yangang Wang, Bingzi Dong
Summary: Chronic kidney diseases (CKD) and cardiovascular diseases (CVD) are common complications in type 2 diabetes mellitus (T2DM), leading to increased risk of cardiovascular and all-cause mortality. Therapeutic strategies to delay CKD and CVD progression in T2DM include ACE inhibitors, ARBs, SGLT-2 inhibitors, and GLP-1 receptor agonists. The use of mineralocorticoid receptor antagonists, such as finerenone, shows promising results in reducing cardiovascular and renal complications in T2DM patients with CKD and/or CHF.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Joao Pedro Ferreira, Zohra Lamiral, John J. McMurray, Karl Swedberg, Dirk J. van Veldhuisen, John Vincent, Patrick Rossignol, Stuart J. Pocock, Bertram Pitt, Faiez Zannad
Summary: The study findings suggest that patients with heart failure with reduced ejection fraction and insulin-treated diabetes benefit more from eplerenone compared to those with diabetes not treated with insulin and individuals without diabetes.
CIRCULATION-HEART FAILURE
(2021)
Article
Urology & Nephrology
Murray Epstein
Summary: Understanding the mechanisms of action of aldosterone and its interaction with the mineralocorticoid receptor (MR) provides a theoretical framework to predict the therapeutic potential of MR antagonists (MRAs) in CKD and heart failure. Recent studies have shown that aldosterone plays a wider role in modulating inflammation, collagen formation, fibrosis, and necrosis, beyond its initial focus on renal excretory function. Blockade of the MR is being investigated as a novel treatment to slow the progression of CKD, as demonstrated in the FIDELIO-DKD study.
AMERICAN JOURNAL OF NEPHROLOGY
(2021)
Review
Medicine, General & Internal
Luca Di Lullo, Carlo Lavalle, Alessia Scatena, Marco Valerio Mariani, Claudio Ronco, Antonio Bellasi
Summary: Chronic kidney disease (CKD) is a common complication of diabetes mellitus and a risk factor for cardiovascular disease. Current medications have not effectively reduced the risk associated with CKD and type 2 diabetes due to inflammation and fibrosis. This review discusses the differences between finerenone and other treatments, as well as potential therapeutic combinations.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Cardiac & Cardiovascular Systems
Joao Pedro Ferreira, Jonathan P. Blatchford, John R. Teerlink, Mikhail N. Kosiborod, Christiane E. Angermann, Jan Biegus, Sean P. Collins, Jasper Tromp, Michael E. Nassif, Mitchell A. Psotka, Josep Comin-Colet, Robert J. Mentz, Martina Brueckmann, Matias Nordaby, Piotr Ponikowski, Adriaan A. Voors
Summary: This study aimed to evaluate the efficacy and safety of empagliflozin versus placebo in patients hospitalized for acute heart failure (AHF), stratified by baseline mineralocorticoid receptor antagonists (MRAs) use. The results showed that empagliflozin produced clinical benefit and was well tolerated, regardless of baseline MRA use.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Review
Endocrinology & Metabolism
Gianluigi Savarese, Felix Lindberg, Gerasimos Filippatos, Javed Butler, Stefan D. Anker
Summary: The overactivation of mineralocorticoid receptors affects multiple physiological systems, and the use of classical MR antagonists has shown improvements in heart failure. However, concerns about side effects and limited tolerability have hindered their implementation in other settings. Non-steroidal MR antagonists have shown potential benefits and better safety profiles. This review provides an overview of the impact of MR overactivation and discusses the potential of non-steroidal MR antagonists.
Article
Endocrinology & Metabolism
Peter Rossing, Stefan D. Anker, Gerasimos Filippatos, Bertram Pitt, Luis M. Ruilope, Andreas L. Birkenfeld, Janet B. McGill, Sylvia E. Rosas, Amer Joseph, Martin Gebel, Luke Roberts, Markus F. Scheerer, George L. Bakris, Rajiv Agarwal
Summary: Finerenone reduces the risk of kidney and cardiovascular events in patients with CKD and type 2 diabetes, irrespective of SGLT2i use.
Article
Peripheral Vascular Disease
Vadym Buncha, Alena Cherezova, Sati Alexander, Irina Baranovskaya, Kathleen A. Coleman, Mary Cherian-Shaw, Michael W. Brands, Jennifer C. Sullivan, Paul M. O'Connor, Mykola Mamenko
Summary: In female rats, the MR-ENaC axis plays a crucial role in determining AngII-dependent hypertension, while its effects are limited in males.
Article
Cardiac & Cardiovascular Systems
Joao Pedro Ferreira, Faiez Zannad, Stuart J. Pocock, Stefan D. Anker, Javed Butler, Gerasimos Filippatos, Martina Brueckmann, Waheed Jamal, Dominik Steubl, Elke Schueler, Milton Packer
Summary: In patients with heart failure and reduced ejection fraction, the effects of empagliflozin were similar in those using or not using MRAs. Empagliflozin treatment was associated with less discontinuation of MRAs.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Paula Aldaz, Amaya Fernandez-Celis, Natalia Lopez-Andres, Imanol Arozarena
Summary: Dexamethasone (DEXA) is commonly used in glioblastoma (GBM) patients to reduce brain inflammation, activating the glucocorticoid receptor (GR) which can influence the mineralocorticoid receptor (MR) signaling. MR signaling in GBM has been shown to have anti-proliferative effects and inhibit the self-renewal of GSCs, while spironolactone (SPI) may not have significant anti-neoplastic potential in GBM.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Pharmacology & Pharmacy
Wen-Jun Gou, Fa-Wei Zhou, Rui Providencia, Bo Wang, Heng Zhang, Shou-Liang Hu, Xiao-Li Gao, Yan-hong Tuo, Yong Zhang, Tian Li
Summary: Mineralocorticoid receptor antagonists (MRA) can effectively reduce mortality and cardiovascular mortality in dialysis patients, improve cardiac function and blood pressure, and demonstrate good safety.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Peter Kolkhof, Amer Joseph, Ulrich Kintscher
Summary: Over the past 30 years, there has been significant progress in understanding the role of aldosterone and mineralocorticoid receptor in cardiovascular and kidney diseases. Ongoing research is focused on developing safer and more effective nonsteroidal MR antagonists.
PHARMACOLOGICAL RESEARCH
(2021)
Review
Urology & Nephrology
Pantelis Sarafidis, Fotini Iatridi, Charles Ferro, Maria-Eleni Alexandrou, Beatriz Fernandez-Fernandez, Mehmet Kanbay, Francesca Mallamaci, Ionut Nistor, Patrick Rossignol, Christoph Wanner, Mario Cozzolino, Alberto Ortiz, ERBP Board
Summary: Chronic kidney disease (CKD) in individuals with type 2 diabetes is a major public health issue. Renin-angiotensin system (RAS) blockers have been the standard treatment, but their effectiveness in reducing cardiovascular events and mortality is limited. Non-steroidal mineralocorticoid receptor antagonists (MRAs) have gained interest due to their better pharmacologic profile. Finerenone, the first compound of this class, has shown promise in reducing kidney disease progression and cardiovascular outcomes in patients with type 2 diabetes.
CLINICAL KIDNEY JOURNAL
(2023)
Article
Urology & Nephrology
Michele Provenzano, Niels Jongs, Priya Vart, Bergur Stefansson, Glenn M. Chertow, Anna Maria Langkilde, John J. McMurray, Ricardo Correa-Rotter, Peter Rossing, C. David Sjostrom, Robert D. Toto, David C. Wheeler, Hiddo J. L. Heerspink
Summary: Dapagliflozin was equally safe and effective in reducing major adverse kidney outcomes in participants with CKD, regardless of whether they were prescribed MRAs at baseline.
KIDNEY INTERNATIONAL REPORTS
(2022)
Article
Peripheral Vascular Disease
Tatsufumi Oka, Yusuke Sakaguchi, Koki Hattori, Yuta Asahina, Sachio Kajimoto, Yohei Doi, Jun-Ya Kaimori, Yoshitaka Isaka
Summary: This study examined the use of mineralocorticoid receptor antagonists (MRA) in chronic kidney disease and found that MRA use was associated with a lower rate of renal replacement therapy initiation. Specifically, MRA users showed a better renal prognosis across various chronic kidney disease subgroups.
Article
Endocrinology & Metabolism
E. Pagnin, V. Ravarotto, G. Maiolino, E. Naso, P. A. Davis, L. A. Calo
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
(2018)
Article
Peripheral Vascular Disease
Giuseppe Maiolino, Michele Battistel, Giulio Barbiero, Valeria Bisogni, Gian Paolo Rossi
AMERICAN JOURNAL OF HYPERTENSION
(2018)
Article
Surgery
Giacomo Rossitto, Giuseppe Maiolino, Livia Lenzini, Valeria Bisogni, Teresa Maria Seccia, Maurizio Cesari, Maurizio Iacobone, Gian Paolo Rossi
Article
Multidisciplinary Sciences
Verdiana Ravarotto, Gianni Carraro, Elisa Pagnin, Giovanni Bertoldi, Francesca Simioni, Giuseppe Maiolino, Matteo Martinato, Linda Landini, Paul A. Davis, Lorenzo A. Calo
Article
Endocrinology & Metabolism
V Ravarotto, F. Simioni, C. Sabbadin, E. Pagnin, G. Maiolino, D. Armanini, L. A. Calo
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
(2019)
Article
Peripheral Vascular Disease
Giacomo Rossitto, Maurizio Cesari, Giulio Ceolotto, Giuseppe Maiolino, Teresa Maria Seccia, Gian Paolo Rossi
JOURNAL OF HUMAN HYPERTENSION
(2019)
Article
Peripheral Vascular Disease
Valeria Bisogni, Martino F. Pengo, Giuseppe Maiolino, Maurizio Cesari, Silvia Lerco, Giacomo Rossitto, Antonio Concistre, Luigi Petramala, Claudio Letizia, Teresa Maria Seccia, Gian Paolo Rossi
Editorial Material
Peripheral Vascular Disease
Giuseppe Maiolino, Peter W. de Leeuw, Daan J. L. van Twist, Giulio Barbiero, Michele Battistel, Garry L. R. Jennings, Gian Paolo Rossi
Article
Endocrinology & Metabolism
Livia Lenzini, Selene Prisco, Paul Emmanuel Vanderriele, Silvia Lerco, Francesca Torresan, Giuseppe Maiolino, Teresa Maria Seccia, Maurizio Iacobone, Gian Paolo Rossi
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2019)
Article
Medical Laboratory Technology
Valeria Bisogni, Giuseppe Maiolino, Giulio Ceolotto, Martino F. Pengo, Rosario Marchese Ragona, Carlo Artusi, Laura Brugnolo, Silvia Lerco, Daniele Borsetto, Piergiorgio Gaudioso, Alessandro Martini, Mario Plebani, Gian Paolo Rossi
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
(2019)
Editorial Material
Peripheral Vascular Disease
Gian Paolo Rossi, Giuseppe Maiolino
Article
Endocrinology & Metabolism
Gian Paolo Rossi, Giuseppe Maiolino, Teresa M. Seccia
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
(2019)
Review
Peripheral Vascular Disease
Teresa M. Seccia, Brasilina Caroccia, Giuseppe Maiolino, Maurizio Cesari, Gian Paolo Rossi
CURRENT HYPERTENSION REPORTS
(2019)
Article
Peripheral Vascular Disease
Teresa M. Seccia, Claudio Letizia, Maria L. Muiesan, Silvia Lerco, Maurizio Cesari, Valeria Bisogni, Luigi Petramala, Giuseppe Maiolino, Roberta Volpin, Gian Paolo Rossi
JOURNAL OF HYPERTENSION
(2020)
